Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment

An efficacy–tolerability pilot study

Emiliano Petrò, Elena Ruffini, Melania Cappuccio, Valeria Guerini, Gloria Belotti, Sara Fascendini, Cristina Licini, Claudio Marcassa

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: This pilot study evaluated the efficacy and safety of prolonged-release oxycodone/naloxone (OXN-PR) in older subjects with chronic pain and mild-to-moderate cognitive impairment. Methods: This was a prospective, observational, open-label study of 45-day duration. Patients with moderate-to-severe chronic pain and naïve to strong opioids were recruited from nursing homes and Alzheimer’s disease centers. OXN-PR was initiated at low doses (5 mg od or bid) and increased to a maximum of 20 mg bid. The primary efficacy endpoint was a pain intensity reduction of ≥30% from baseline (T0) to 15 days after OXN-PR initiation, as assessed by a numerical rating scale or the Pain Assessment in Advanced Dementia scale. Other assessments included the Barthel activities of daily living index, Neuropsychiatric Inventory, Bowel Function Index, and adverse events. Results: The analysis included 53 patients (mean age, 83.0 years; mean Mini-Mental State Examination score, 18.6) with severe pain (median Numerical Rating Scale/Pain Assessment in Advanced Dementia 6) and substantial impairment in daily functioning (mean Barthel index, 32.2). The primary endpoint was achieved by 92.4% of patients. OXN-PR significantly reduced mean pain intensity from baseline to study end (numerical rating scale, 6.6±1.0 vs 2.3±1.1, P

Original languageEnglish
Pages (from-to)559-569
Number of pages11
JournalNeuropsychiatric Disease and Treatment
Volume12
DOIs
Publication statusPublished - Mar 2 2016

Fingerprint

Oxycodone
Naloxone
Chronic Pain
Pain Measurement
Pain
Dementia
Activities of Daily Living
Nursing Homes
Opioid Analgesics
Alzheimer Disease
Safety
Equipment and Supplies
Cognitive Dysfunction

Keywords

  • Alzheimer’s disease
  • Cognitive impairment
  • Dementia
  • Elderly
  • Oxycodone/naloxone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment : An efficacy–tolerability pilot study. / Petrò, Emiliano; Ruffini, Elena; Cappuccio, Melania; Guerini, Valeria; Belotti, Gloria; Fascendini, Sara; Licini, Cristina; Marcassa, Claudio.

In: Neuropsychiatric Disease and Treatment, Vol. 12, 02.03.2016, p. 559-569.

Research output: Contribution to journalArticle

Petrò, Emiliano ; Ruffini, Elena ; Cappuccio, Melania ; Guerini, Valeria ; Belotti, Gloria ; Fascendini, Sara ; Licini, Cristina ; Marcassa, Claudio. / Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment : An efficacy–tolerability pilot study. In: Neuropsychiatric Disease and Treatment. 2016 ; Vol. 12. pp. 559-569.
@article{b778787f4e1a4fc0a8a9303993e23919,
title = "Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment: An efficacy–tolerability pilot study",
abstract = "Objective: This pilot study evaluated the efficacy and safety of prolonged-release oxycodone/naloxone (OXN-PR) in older subjects with chronic pain and mild-to-moderate cognitive impairment. Methods: This was a prospective, observational, open-label study of 45-day duration. Patients with moderate-to-severe chronic pain and na{\"i}ve to strong opioids were recruited from nursing homes and Alzheimer’s disease centers. OXN-PR was initiated at low doses (5 mg od or bid) and increased to a maximum of 20 mg bid. The primary efficacy endpoint was a pain intensity reduction of ≥30{\%} from baseline (T0) to 15 days after OXN-PR initiation, as assessed by a numerical rating scale or the Pain Assessment in Advanced Dementia scale. Other assessments included the Barthel activities of daily living index, Neuropsychiatric Inventory, Bowel Function Index, and adverse events. Results: The analysis included 53 patients (mean age, 83.0 years; mean Mini-Mental State Examination score, 18.6) with severe pain (median Numerical Rating Scale/Pain Assessment in Advanced Dementia 6) and substantial impairment in daily functioning (mean Barthel index, 32.2). The primary endpoint was achieved by 92.4{\%} of patients. OXN-PR significantly reduced mean pain intensity from baseline to study end (numerical rating scale, 6.6±1.0 vs 2.3±1.1, P",
keywords = "Alzheimer’s disease, Cognitive impairment, Dementia, Elderly, Oxycodone/naloxone",
author = "Emiliano Petr{\`o} and Elena Ruffini and Melania Cappuccio and Valeria Guerini and Gloria Belotti and Sara Fascendini and Cristina Licini and Claudio Marcassa",
year = "2016",
month = "3",
day = "2",
doi = "10.2147/NDT.S98511",
language = "English",
volume = "12",
pages = "559--569",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment

T2 - An efficacy–tolerability pilot study

AU - Petrò, Emiliano

AU - Ruffini, Elena

AU - Cappuccio, Melania

AU - Guerini, Valeria

AU - Belotti, Gloria

AU - Fascendini, Sara

AU - Licini, Cristina

AU - Marcassa, Claudio

PY - 2016/3/2

Y1 - 2016/3/2

N2 - Objective: This pilot study evaluated the efficacy and safety of prolonged-release oxycodone/naloxone (OXN-PR) in older subjects with chronic pain and mild-to-moderate cognitive impairment. Methods: This was a prospective, observational, open-label study of 45-day duration. Patients with moderate-to-severe chronic pain and naïve to strong opioids were recruited from nursing homes and Alzheimer’s disease centers. OXN-PR was initiated at low doses (5 mg od or bid) and increased to a maximum of 20 mg bid. The primary efficacy endpoint was a pain intensity reduction of ≥30% from baseline (T0) to 15 days after OXN-PR initiation, as assessed by a numerical rating scale or the Pain Assessment in Advanced Dementia scale. Other assessments included the Barthel activities of daily living index, Neuropsychiatric Inventory, Bowel Function Index, and adverse events. Results: The analysis included 53 patients (mean age, 83.0 years; mean Mini-Mental State Examination score, 18.6) with severe pain (median Numerical Rating Scale/Pain Assessment in Advanced Dementia 6) and substantial impairment in daily functioning (mean Barthel index, 32.2). The primary endpoint was achieved by 92.4% of patients. OXN-PR significantly reduced mean pain intensity from baseline to study end (numerical rating scale, 6.6±1.0 vs 2.3±1.1, P

AB - Objective: This pilot study evaluated the efficacy and safety of prolonged-release oxycodone/naloxone (OXN-PR) in older subjects with chronic pain and mild-to-moderate cognitive impairment. Methods: This was a prospective, observational, open-label study of 45-day duration. Patients with moderate-to-severe chronic pain and naïve to strong opioids were recruited from nursing homes and Alzheimer’s disease centers. OXN-PR was initiated at low doses (5 mg od or bid) and increased to a maximum of 20 mg bid. The primary efficacy endpoint was a pain intensity reduction of ≥30% from baseline (T0) to 15 days after OXN-PR initiation, as assessed by a numerical rating scale or the Pain Assessment in Advanced Dementia scale. Other assessments included the Barthel activities of daily living index, Neuropsychiatric Inventory, Bowel Function Index, and adverse events. Results: The analysis included 53 patients (mean age, 83.0 years; mean Mini-Mental State Examination score, 18.6) with severe pain (median Numerical Rating Scale/Pain Assessment in Advanced Dementia 6) and substantial impairment in daily functioning (mean Barthel index, 32.2). The primary endpoint was achieved by 92.4% of patients. OXN-PR significantly reduced mean pain intensity from baseline to study end (numerical rating scale, 6.6±1.0 vs 2.3±1.1, P

KW - Alzheimer’s disease

KW - Cognitive impairment

KW - Dementia

KW - Elderly

KW - Oxycodone/naloxone

UR - http://www.scopus.com/inward/record.url?scp=84960194006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960194006&partnerID=8YFLogxK

U2 - 10.2147/NDT.S98511

DO - 10.2147/NDT.S98511

M3 - Article

VL - 12

SP - 559

EP - 569

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -